In the case of EBV-positive GC, cells expressed the interleukin IL-15Rα receptor binds to IL 15 and allows the increase of natural killer cells, in addition to the regulation of the JAK/STAT pathway and thyrosine kinase pathways such as MAPK and PI3K (70), at a lower level than EBV-negative cells due to promoter hypermethylation (43); therefore, administration of IL-15 to stimulate immune responses against cancer could be a promising strategy in GC. This evidence concerns the gene SOAT1 and gastric cancer.